You are here

Development of a topical fixed-dose combination drug for peripheral neuropathic pain.

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS120354-01
Agency Tracking Number: R41NS120354
Amount: $699,491.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NINDS
Solicitation Number: NS20-009
Timeline
Solicitation Year: 2020
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-09-30
Award End Date (Contract End Date): 2022-08-31
Small Business Information
4685 CONVOY ST #210
San Diego, CA 92111-2339
United States
DUNS: 078868444
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 ANGELA HANSEN
 (858) 546-9044
 ahansen@winsantor.com
Business Contact
 STANLEY KIM
Phone: (858) 336-8094
Email: skim@winsantor.com
Research Institution
 UNIVERSITY OF CALIFORNIA, SAN DIEGO
 
9500 Gilman Drive, Mail Code 0934
LA JOLLA, CA 92093-0934
United States

 Nonprofit college or university
Abstract

PROJECT SUMMARY
An estimated 30 million people in the United States suffer from some form of peripheral neuropathy, a
condition that develops as a result of damage to the peripheral nervous system. The top two major causes of
peripheral neuropathy in the US are diabetes mellitus (both T1DM and T2DM) and chemotherapeutic agents.
Currently, there are no FDA-approved treatments to prevent or reverse diabetic peripheral neuropathy (DPN)
and chemotherapy-induced peripheral neuropathy (CIPN) other than those that simply treat the symptomatic
pain. The founders of WinSanTor have demonstrated that peripheral neuron growth is restrained by cholinergic
activation of the M1 receptor (M1R) via regulation of mitochondrial respiration. M1R antagonists promote
neuronal growth and prevent and/or reverse multiple indices of neuropathy and associated neuropathic pain in
nonclinical models of diabetes and CIPN, after chronic administration. Consistent with this, a pilot clinical trial
by our academic collaborator using the non-selective muscarinic receptor antagonist oxybutynin, confirmed
reversal of intra-epidermal nerve fiber (IENF) loss in subjects with type 2 diabetes after 5 months of dermal
topical treatment, with concurrent reduction of pain. M1R antagonists offer a potentially disease-modifying
therapeutic approach for DPN and CIPN. While muscarinic antagonists have been shown to reverse pain after
chronic administration (5 months), they do not have acute (minutes to hours following a single application) anti-
pain effects. An ideal therapeutic approach would combine both acute palliative and chronic disease-modifying
properties, both to retain patient compliance and also block chronification of pain – the concept that ongoing
acute pain permanently modifies sensory processing systems. Given the potent effects of topical analgesics
such as lidocaine in acutely alleviating pain in some diabetic and CIPN patients, and the promising disease-
modifying effects of topical pirenzepine on neuropathic pain, we propose to develop a fixed-dose combination
(FDC) product that offers acute pain relief to disrupt the chronification of pain and establish patient medication
compliance that also prevents and/or reverses established degenerative neuropathy and associated
neuropathic pain. FDC products, which contain two or more separate active ingredients that target different
pathways, are a proven way of addressing indications with complex etiology, and offer enhanced efficacy
and/or improved disease management than either monotherapy alone. Furthermore, FDCs reduce patient
treatment burden and improve compliance, due to the acute pain relief potential. To develop this novel FDC
product, we propose to 1) develop an FDC of lidocaine and pirenzepine topical formulation, and 2) test the
treatment regime of co-administration of topical lidocaine 5% and pirenzepine 4% in reversing indices of
neuropathy and neuropathic pain in mouse models of diabetes and CIPN. The success of Phase I will provide
strong support for a Phase II project, where additional pharmacology safety and toxicology studies, as well as
CMC work, will be conducted to support an FDA IND submission.PROJECT NARRATIVE
Thirty million Americans suffer from some type of peripheral neuropathy, a condition that develops as a result
of damage to the peripheral nervous system and is frequently associated with pain. There are no current FDA-
approved treatments that target the pathological processes underlying peripheral neuropathy and provide pain
relief. WinSanTor is developing a novel fixed-dose combination product that offers acute pain relief to disrupt
the chronification of pain and establish patient medication compliance and also prevents and/or reverses
established degenerative neuropathy and associated neuropathic pain caused by diabetes and chemotherapy.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government